Deutsche Bank upgraded shares of Smith & Nephew (NYSE:SNN) from a sell rating to a hold rating in a research note issued to investors on Friday morning, The Fly reports.
Several other equities research analysts have also commented on the stock. Zacks Investment Research upgraded shares of Smith & Nephew from a hold rating to a buy rating and set a $42.00 price objective on the stock in a research report on Wednesday. Canaccord Genuity reiterated a buy rating on shares of Smith & Nephew in a research report on Thursday, November 1st. Finally, HSBC lowered shares of Smith & Nephew from a buy rating to a hold rating in a research report on Tuesday, October 16th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $42.00.
Shares of NYSE SNN traded up $0.72 during trading on Friday, hitting $37.93. 963,436 shares of the company were exchanged, compared to its average volume of 472,477. The firm has a market capitalization of $16.27 billion, a P/E ratio of 19.96, a PEG ratio of 3.02 and a beta of 0.60. Smith & Nephew has a 1 year low of $32.22 and a 1 year high of $39.85. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 2.13.
Smith & Nephew Company Profile
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Featured Article: Book Value Per Share in Stock Trading
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.